Item Posts Archive - Page 39 of 1770 - Medivizor
Navigation Menu

Comparing the safety of palbociclib combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer

Comparing the safety of palbociclib combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer

Posted by on Dec 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the safety profile of palbociclib (Ibrance) combined with either fulvestrant (Faslodex) or letrozole (Femara) in patients with hormone-receptor-positive (HR+) and HER2 negative (HER2 -) advanced breast cancer (BC). The data showed that both palbociclib regimens were safe and tolerated in these patients with some...

Read More

Comparing the effectiveness of IVF/ICSI versus IUI in unexplained infertility

Comparing the effectiveness of IVF/ICSI versus IUI in unexplained infertility

Posted by on Dec 30, 2022 in Infertility | 0 comments

In a nutshell The study compared the pregnancy rates for intrauterine insemination (IUI) and in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) in couples with unexplained infertility. The data concluded that IVF/ICSI is a better treatment option than IUI for unexplained infertility. Some background Infertility is the inability to...

Read More

Evaluating the effectiveness of intralipid administration to improve in vitro fertilization outcomes

Evaluating the effectiveness of intralipid administration to improve in vitro fertilization outcomes

Posted by on Dec 9, 2022 in Infertility | 0 comments

In a nutshell The study evaluated the effectiveness of intralipid administration to improve in vitro fertilization (IVF) outcomes. The main finding was that injecting intralipid in women during IVF showed promising results in improving pregnancy and live birth rates. Some background Infertility is faced by many couples and IVF is one way to achieve...

Read More

Comparing the effectiveness of TAS-102 versus regorafenib for the treatment of patients with metastatic colorectal cancer.

Comparing the effectiveness of TAS-102 versus regorafenib for the treatment of patients with metastatic colorectal cancer.

Posted by on Dec 9, 2022 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of TAS-102 (Lonsurf; trifluridine-tipiracil) versus regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that TAS-102 had better oncologic outcomes than regorafenib in these patients. Some background Colorectal cancer (CRC) is one of the...

Read More

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Posted by on Dec 9, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of ramucirumab (Cyramza) and pembrolizumab (Keytruda) versus standard of care (SOC) in previously treated patients with advanced non-small cell lung cancer (NSCLC). The data showed that ramucirumab and pembrolizumab significantly improved overall survival compared with SOC in...

Read More